1. Search Result
Search Result
Results for "

Carboxypeptidase Y

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Fluorescent Dye

5

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2981

    Carboxypeptidase Y; EC 3.4.16.1

    Carboxypeptidase Others
    Carboxypeptidase C is a carboxypeptidase, is often used in biochemical studies. Carboxypeptidase C removes COOH-terminal lysine, arginine, and proline, as well as all other neutral, aliphatic, aromatic, and the acidic protein amino acids of a peptide chain .
    Carboxypeptidase C
  • HY-W010955

    NSC 334018

    Biochemical Assay Reagents Others
    Z-Phe-Leu-OH (NSC 334018) is a substrate for carboxypeptidase Y (CPY). Z-Phe-Leu-OH is incubated with recombinant CPY to determine peptidase activity .
    Z-Phe-Leu-OH
  • HY-P1469

    Bradykinin Receptor Cardiovascular Disease Endocrinology
    Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).
    Bradykinin (1-6)
  • HY-12827

    Carboxypeptidase Others
    Sortin1 is a vacuolar protein sorting inhibitor that targets carboxypeptidase Y (CPY). Sortin1 is a soluble and membrane vacuolar marker molecule in plants and yeast .
    Sortin1
  • HY-E70334

    Endogenous Metabolite Others
    Carboxypeptidase Y, Baker's yeast (S. cerevisiae) is a biocatalyst and a key enzyme in new biocatalyst technology. Enzyme engineering focuses on enhancing enzyme reaction kinetics, substrate selectivity, and activity under harsh conditions such as low or high pH. By introducing stimulus responsiveness to these enzyme modifications, dynamic control of activity is also possible .
    Carboxypeptidase Y, Baker's yeast (S. cerevisiae)
  • HY-P3791

    Fluorescent Dye Others
    N-Succinyl-Ile-Ile-Trp-AMC is a peptide-based fluorescent substrate or probe for carboxypeptidase Y (CPY) .
    N-Succinyl-Ile-Ile-Trp-AMC
  • HY-N16373

    Carboxypeptidase Cardiovascular Disease
    Belactin A (Compound 4) is a Carboxypeptidase Y (CP-Y) inhibitor with a IC50 of 0.18  μM. Belactin A can be isolated from Streptomyces erythraeus. Belactin A has antihypertensive and general pump inhibitory activities .
    Belactin A
  • HY-114118S1

    Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8 tetraTFA
  • HY-114118S

    Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: